幹細胞の世界市場:2027年までの年成長率は15.3%(2022-2027年予測)

出版:BCC Research(BCCリサーチ) 出版年月:2023年3月

Global Market for Stem Cells
幹細胞の世界市場:2027年までの年成長率は15.3%(2022-2027年予測)

ページ数139
価格
 シングルユーザライセンスUSD 5,500
 2-5ユーザライセンスUSD 6,600
 サイトライセンスUSD 7,920
 エンタープライズライセンスUSD 9,504
種別英文調査報告書

レポート目次  お問合せ・ご注文  価格・納期について

無料サンプル

Report Highlights

The global stem cell market reached $32.1 billion in 2022 and should reach $65.6 billion by 2027, with a compound annual growth rate (CAGR) of 15.3% during the forecast period of 2022-2027.

Summary:

Stem cells are the first cells formed when an egg and a sperm join, and the resultant zygote begins to divide. They are the precursors of all the different types of cells that make up the body. They are characterized by self-renewal, which is the capacity to continue dividing to make ever-larger populations of stem cells, as well as the capacity to differentiate into any mature cell type when they receive appropriate chemical instructions.

Several broad categories of stem cells exist, including embryonic stem cells, which are derived from blastocysts; fetal stem cells, which are obtained from aborted fetuses; adult stem cells, which are found in adult tissues; cord blood stem cells, which are isolated from umbilical tissue; cancer stem cells, which give rise to a clonal populations of cells that form tumors or disperse in the body; and animal stem cells, which are derived from non-human sources.

Applications

In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult organisms, stem and progenitor cells act as a repair system for the body, replenishing specialized cells. Researchers are interested in the potential for using stem cells to treat conditions, including diabetes, cardiovascular disease and neurological disorders, by replacing defective cells and tissues; ideally, stem cells function as the raw material from which new populations of normal differentiated cells and tissues develop.

Stem cells can also be used in pharmaceutical research to improve drug target validation and toxicology screening. This is of intense interest to pharmaceutical companies, as it offers a safer alternative to the use of living organisms, including humans, for some aspects of drug testing. Stem cells are also being studied for their ability to improve both the understanding and treatment of birth disorders.

Research and Commercialization

A sizeable stem cell research product market has emerged to facilitate the research resulting from interest in stem cell applications. Large companies selling stem cell research products include Invitrogen, BD Biosciences, Thermo Fisher Scientific and Millipore. Products offered by these companies include antibodies to stem cell antigens, bead-based stem cell separation systems, stem cell protein purification and analysis tools, tools for DNA- and RNA-based Characterization of stem cells, stem cell culture and media reagents, stem-cell-specific growth factors and cytokines, tools for stem cell gene regulation, a range of stem cell services, tools for in vivo and in vitro stem cell tracking, and stem cell lines.

The major market for stem cells will be their use in the treatment of disease, and there are already numerous companies specializing in developing stem cells directed toward specific disease targets. This market opportunity is still largely at an early, experimental stage. The main exception is the use of stem cells taken from the patient’s own bone marrow to treat conditions such as leukemia, which is a failure of normal hematopoiesis (i.e., formation of blood cells). This use of stem cells is well established.

A third market opportunity has arisen in the stem cell field based on the collection and preservation of stem cells from the umbilical cord blood after a baby is born. The cells are kept frozen in “cord blood banks” so they may be used by the donor later in life to treat appropriate diseases. This use of stem cells is not generally endorsed by the medical profession, but it has given rise to a kind of medical tourism.

Report Scope:

This report discusses the implications of stem cell research and commercial trends in the context of the current size and growth of the pharmaceutical market, both in global terms and analyzed by the most important national markets. The important technologies supporting stem cells are reviewed, and the nature and structure of the stem cell industry is discussed, with profiles of the leading companies, including recent merger and acquisition (M&A) activity. Five-year sales forecasts are provided for the national markets and the major therapeutic categories of the products involved.

Report Includes:

– 18 data tables and 14 additional tables
– An up-to-date overview and analysis of the global markets for (biological) stem cells and related products
– Analyses of the global market trends, with historic revenue data for 2021, estimates for 2022 and 2023, and projections of compound annual growth rates (CAGRs) through 2027
– Estimation of the actual market size and revenue forecast for global stem cells market in USD million terms, and corresponding market share analysis by product, application, end user, and region
– Highlights of emerging technology trends, market opportunities and deterrents estimating current and future demand of stem cells related products and their derivatives for drug discovery
– Discussion of market dynamics that impact the growth of the market for biological stem cells, clinical applications, market regulations, industry structure, and penetration of technologies within the biotech industry
– Review of the patents and patent applications on stem cell research, and corresponding research/scientific publications during the analysis period
– Competitive landscape of the key manufacturers and suppliers of the stem cell-related drug market, their product portfolios, financial updates, and major growth strategies within the marketplace
– Company profiles of major players within the industry, including 3-D Matrix Medical Technology, International Stem Cell Corp., ReNeuron Group, and U.S. Stem Cell Inc.


目次

Table of Contents
Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing the Study
1.3 What’s New in This Update?
1.4 Scope of Report
1.5 Market Analyses and Forecasts
1.6 Methodology
1.7 Intended Audience
1.8 Information Sources
1.9 Analyst’s Credentials
1.10 BCC Custom Research
1.11 Related BCC Research Reports
Chapter 2 Summary and Highlights
2.1 Definitions
2.2 Applications
2.3 Research and Commercialization
2.4 Funding
2.5 Market
Chapter 3 Overview
3.1 Cells
3.2 Stem Cells
3.2.1 Induced Pluripotent Stem Cells
Chapter 4 Stem Cell Research
4.1 History
4.2 Embryonic Stem Cells
4.2.1 Growth and Identification of Embryonic Stem Cells
4.2.2 Stimulating Embryonic Stem Cells to Differentiate
4.3 Adult Stem Cells
4.3.1 Mesenchymal Stem Cells
4.3.2 Hematopoietic Stem Cells
4.3.3 Neural Stem Cell
4.3.4 Endothelial Progenitor Cell
4.3.5 Epithelial Stem Cell
4.3.6 Very Small Embryonic-Like Cell
4.4 Cord Blood Stem Cells
4.5 Induced Pluripotent Stem Cells
4.5.1 Nuclear Reprogramming
4.6 Cell-Based Therapeutics
4.6.1 Embryonic-Derived Stem Cells
4.6.2 Adult and Progenitor-Derived Stem Cells
4.6.3 Engineered Stem Cells for Transplantation
4.7 Therapeutic Stem Cell Banking
4.8 Stem Cell-Based Biomedical Research
4.9 Stem Cell Research Centers
4.10 Regulation of Stem Cell Research
4.10.1 National Regulatory Measures
4.11 Practicalities of Stem Cell Research and Production
4.11.1 Stem Cell Production
4.11.2 Stem Cell Acquisition
4.11.3 Stem Cell Production Economics
4.11.4 Customized Therapy
4.11.5 Banks
4.11.6 Novel Stem Cell Production Developments
4.11.7 Isolation and Engineering
4.11.8 Adult Stem Cells
4.11.9 Embryonic Stem Cells
4.11.10 Induced Pluripotent Stem Cells
4.11.11 Bioprinting
4.12 Stem Cell Banking
4.13 Impact of COVID-19 on Stem Cell Therapy
4.13.1 Impact of COVID-19 on iPSCs
Chapter 5 Stem Cell Applications
5.1 Regenerative Medicine
5.2 Current Stem Cell Therapy Applications
5.2.1 Cancer
Chapter 6 Stem Cell Patents
6.1 General Background on Patents
6.1.1 Stem Cell Patents
6.2 Policies by Country
6.2.1 United States
6.2.2 Canada
6.2.3 European Patent Convention
6.2.4 United Kingdom
6.2.5 Germany
6.2.6 Japan
6.2.7 China
4.3 Induced Pluripotent Stem Cells
4.4 Recent Patent Activity
4.5 Clinical Trials
Chapter 7 Stem Cell Markets
7.1 Markets for Stem Cells
7.2 Market Dynamics
7.2.1 Market Drivers
7.2.2 Market Opportunities by Therapeutic Class
7.3 Global Market Estimates and Forecasts
7.3.1 North America
7.3.2 Europe
7.3.3 Asia-Pacific
7.3.4 Rest of the World
Chapter 8 Emerging Technologies in the Market
8.1 Stem Cell Market in 2022 and Beyond
8.1.1 Oncology Applications
8.1.2 Dermatology Applications
8.1.3 Genetically Modified Stem Cells
8.1.4 Disease Modeling
8.1.5 Sustainable Meat Sources
8.1.6 Bioprinting
8.1.7 Surgery
8.1.8 COVID-19
8.2 Emerging Technologies in Stem Cell Research
Chapter 9 Company Profiles
3-D MATRIX MEDICAL TECHNOLOGY
ATHERSYS INC.
BEIKE BIOTECHNOLOGY CO. LTD.
BRAINSTORM CELL THERAPEUTICS INC.
CELYAD
CYTORI THERAPEUTICS INC.
EPISTEM LTD.
FUJIFILM CELLULAR DYNAMICS INC. (FCDI)
GAMIDA CELL LTD.
HYBRID ORGAN GMBH
INTERNATIONAL STEM CELL CORP.
ARTERIOCYTE MEDICAL SYSTEMS INC. (ISTO BIOLOGICS)
LISATA THERAPEUTICS.
MESOBLAST LTD.
RENEURON GROUP
STEMEDICA CELL TECHNOLOGIES INC.
STEMINA BIOMARKER DISCOVERY INC.
STEMPEUTICS
U.S. STEM CELL INC.
VERICEL CORP.
VERASTEM INC.
VIACYTE INC.
VITRO BIOPHARMA
WICELL RESEARCH INSTITUTE
Chapter 10 Appendix: Glossary

List of Tables
Summary Table : Global Stem Cell Market, by Region, Through 2027
Table 1 : Funding for Various Research, 2016-2023 (Estimated)
Table 2 : Bioprinting Emerging Platforms
Table 3 : Countries Engaged in the ISCBI Program
Table 4 : Patents Related to Induced Pluripotent Stem-Cells, 2021 and 2022
Table 5 : Stem Cell Patents, by Type, 2021
Table 6 : Select Clinical Trials on Stem Cell Research in 2021
Table 7 : Select Clinical Trials on Stem Cell Research in 2022
Table 8 : Select Clinical Trials on Stem Cells in January 2023
Table 9 : Clinical Trials on Various Heart Conditions, 2021-2022
Table 10 : Clinical Trials on Neurodegenerative Diseases, 2021-2022
Table 11 : Global Stem Cell Market, by Region, Through 2027
Table 12 : North American Stem Cell Market, by Country, Through 2027
Table 13 : U.S. Stem Cell Market, Through 2027
Table 14 : Canadian Stem Cell Market, Through 2027
Table 15 : Mexican Stem Cell Market, Through 2027
Table 16 : Regulatory Scenario of European Country
Table 17 : European Stem Cell Market, by Country, Through 2027
Table 18 : French Stem Cell Market, Through 2027
Table 19 : German Stem Cell Market, Through 2027
Table 20 : Italian Stem Cell Market, Through 2027
Table 21 : Spanish Stem Cell Market, Through 2027
Table 22 : U.K. Stem Cell Market, Through 2027
Table 23 : Asia-Pacific Stem Cell Policies, 2021
Table 24 : Asia-Pacific Stem Cell Market, by Country, Through 2027
Table 25 : List of Approved Human Somatic Cell-Processed Products in Japan
Table 26 : Japanese Stem Cell Market, Through 2027
Table 27 : Chinese Stem Cell Market, Through 2027
Table 28 : List of Approved Stem Cell Therapies and Clinical Trials on Stem Cell Therapies for Diseases in India
Table 29 : Cost of Stem Cell Therapy in India, U.K. and U.S.
Table 30 : Indian Stem Cell Market, Through 2027
Table 31 : Rest of the World Stem Cell Market, Through 2027

List of Figures
Summary Figure : Global Stem Cell Market, by Region, 2020-2027
Figure 1 : Early Development of Embryo
Figure 2 : Funding for Stem Cell Research, 2016-2023 (Estimated)
Figure 3 : Stem Cell Therapy Application in Cancer Treatment
Figure 4 : Distribution of Clinical Trial Phases on Stem Cell Therapy, 2023


    お問合せフォーム

    • *のある項目は必須項目です。

    • レポートのタイトルは自動で入ります。

    • 無料サンプルはご購入を検討されている方向けのレポート形式等確認用資料です。
      重要記述や数値は記載されていません。予めご了承ください。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com